J Clin Oncol. 1996 Jun;14(6):1961-3. doi: 10.1200/JCO.1996.14.6.1961.
The American Society of Clinical Oncology (ASCO) supports the elimination of tobacco products. Toward that goal, ASCO urges the adoption of national policy that strengthens regulation of the sale, promotion, and distribution of such products. To reduce cancer mortality, our regulatory policies must recognize that the nicotine within tobacco is an addictive substance, the use of which leads to 30% of all cancer deaths and a total of 419,000 deaths each year.
Tobacco-related advertising and promotion should be banned. At a minimum, national policies should: ban billboards; limit advertising to black and white text only; prohibit the sale or giveaway of products that contain tobacco brand names or logos; prohibit brand name sponsorship of sporting or entertainment events; and require stronger and more prominent warning labels on all tobacco products.
Despite existing state laws prohibiting sale of tobacco products to minors, children are able to buy such products easily. National regulation of the sale and distribution of tobacco products is necessary to eliminate children's access to tobacco. Where sales are permitted, they should be limited to face-to-face purchases by individuals 18 and older. Vending machines and other means of distributing tobacco without a face-to-face purchase should be outlawed.
To the extent tobacco sales are allowed to continue, the federal government should mandate that the tobacco industry contribute substantial funds for a national public education campaign to prevent young people from smoking and other tobacco use.
ASCO has long advocated a substantial increase (in the range of $2) in the federal excise tax on cigarettes and other tobacco products- a measure known to decrease consumption, particularly among children. Revenue from a tax on tobacco products should be used to support retraining for tobacco farmers, biomedical research, health care delivery, and antitobacco education.
United State trade policies should discourage the export of tobacco products and manufacturing to foreign markets. At a minimum, United States tobacco companies selling or manufacturing tobacco products in foreign markets that have not developed comparable health warning labels should be required to retain United States warning labels.
Physicians, nurses, and other health care professionals-especially those in primary care disciplines-have the opportunity and responsibility to assist patients' efforts to quit tobacco use and to ensure that nonsmokers continue to avoid the addiction. Oncology specialists should discuss the causal relationship between tobacco use and cancer as well as a variety of other chronic diseases and assist, as required, the patient and family members to end tobacco dependency. In addition, health care professionals must advocate that public and private insurers be required to provide health care coverage for medically necessary interventions, such as counseling and nicotine transdermal systems.
美国临床肿瘤学会(ASCO)支持消除烟草制品。为实现这一目标,ASCO敦促采取国家政策,加强对此类产品销售、促销和分销的监管。为降低癌症死亡率,我们的监管政策必须认识到烟草中的尼古丁是一种成瘾物质,其使用导致每年30%的癌症死亡,总计41.9万人死亡。
应禁止与烟草相关的广告和促销。至少,国家政策应:禁止广告牌;将广告限制为仅黑白文字;禁止销售或赠送带有烟草品牌名称或标识的产品;禁止品牌赞助体育或娱乐活动;并要求在所有烟草产品上设置更强有力、更醒目的警示标签。
尽管现有州法律禁止向未成年人销售烟草制品,但儿童仍能轻易买到此类产品。对烟草制品的销售和分销进行国家监管对于消除儿童获取烟草的途径至关重要。在允许销售的地方,应仅限于18岁及以上个人的面对面购买。自动售货机和其他无需面对面购买即可分发烟草的方式应被取缔。
在允许继续销售烟草的范围内,联邦政府应强制烟草行业为全国性的公众教育活动提供大量资金,以防止年轻人吸烟和使用其他烟草制品。
ASCO长期以来一直主张大幅提高(约2美元)对香烟和其他烟草制品的联邦消费税——这一措施已知可减少消费,尤其是在儿童中。烟草制品税的收入应用于支持对烟农的再培训、生物医学研究、医疗保健服务和反烟草教育。
美国贸易政策应不鼓励向国外市场出口烟草制品和进行烟草制造。至少,在美国境外市场销售或制造烟草制品且这些市场尚未制定类似健康警示标签的美国烟草公司,应被要求保留美国的警示标签。
医生、护士和其他医疗保健专业人员——尤其是初级保健领域的人员——有机会和责任协助患者戒烟,并确保非吸烟者继续避免成瘾。肿瘤学专家应讨论烟草使用与癌症以及各种其他慢性疾病之间的因果关系,并根据需要协助患者及其家庭成员戒除烟草依赖。此外,医疗保健专业人员必须倡导要求公共和私人保险公司为诸如咨询和尼古丁透皮系统等医疗必需的干预措施提供医疗保险。